Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.

Leech AA, Burgess JF, Sullivan M, Kuohung W, Horný M, Drainoni ML, Christiansen CL, Linas BP. Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States. AIDS (London, England). 2018 Nov;32(32). 2787-2798. PMID: 30234602 [PubMed]

Abstract

The aim of this study was to investigate the value of coformulated Tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) for preexposure prophylaxis (PrEP) for conception in the U.S. and to identify scenarios in which 'Undetectable = Untransmittable' (U = U) may not be adequate, and rather, PrEP or assisted reproduction would improve outcomes.